Streetbeat News

Analyst Ratings

YEXT

DA Davidson analyst Tom White maintains a Neutral rating on Yext (NYSE:YEXT) and raises the price target from $6.5 to $7.25.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 9:23 pm

CCL

NCLH

RCL

Carnival Corporation (NYSE:CCL) shares are trading higher after Stifel maintained a Buy rating and raised its price target from $25 to $26, citing underperformance compared to peers as a buying opportunity. Stifel anticipates Carnival could raise its full-year guidance in its upcoming report. This comes as competitors Norwegian Cruise Line Holdings Ltd. (NYSE:NCLH) and Royal Caribbean Cruises Ltd. (NYSE:RCL) reported better-than-expected earnings and raised guidance due to increased travel demand. Carnival's stock is trading around its 50-day moving average with a significant short interest. A long-term forecast suggests a challenging outlook for Carnival's stock price.

Portfolio Pulse from Erica Kollmann

March 08, 2024 | 9:01 pm

FHN

Barclays analyst Jared Shaw initiates coverage on First Horizon (NYSE:FHN) with an Overweight rating and a price target of $18.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 8:59 pm

EQT

EQT Corporation's (NYSE:EQT) short interest has decreased by 6.41%, now representing 4.09% of its available trading shares. This reduction in short interest, from 14.36 million shares, suggests a more bullish market sentiment towards EQT. The current short interest is below the peer group average of 6.57%, indicating less bearish sentiment compared to its peers. Short interest is a key indicator of market sentiment, and a decrease often suggests a positive outlook on the stock.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 8:45 pm

MRNA

Financial giants have shown a bullish stance on Moderna (NASDAQ:MRNA) through recent options trading, with a mix of bullish and bearish trades observed. The trading activity suggests a target price range of $40.0 to $115.0 for MRNA over the next three months. Moderna, a commercial-stage biotech company, has seen its mRNA technology gain rapid validation, especially with its COVID-19 vaccine. The current trading volume is 2,962,331 with the stock price at $99.48. Analysts have given mixed reviews, with an average target price of $100.67, ranging from $86 to $125.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 8:31 pm

AZO

Deep-pocketed investors have shown a divided sentiment towards AutoZone (NYSE:AZO), with a bearish tilt observed through Benzinga's options scanner. The scanner highlighted 16 unusual options activities, with a price focus between $2600 and $3400. The analysis of these options shows a mix of bullish and bearish positions, with a higher total trade price for calls. AutoZone, a leading retailer of aftermarket automotive parts, has its stock currently positioned at $3124.01, with professional analysts offering mixed ratings and price targets ranging from $3025 to $3400.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 8:30 pm

IGMS

IGM Biosciences (NASDAQ:IGMS) has seen a variety of analyst opinions over the past three months, with recent ratings showing a shift towards a more bullish outlook. Analysts have set a 12-month price target average of $17.5 for IGMS, marking a significant increase from the previous $9.00 average. This change reflects a positive sentiment based on the company's performance and market conditions. IGM Biosciences is a biotech firm focused on developing antibody therapeutics for various diseases, showing strong revenue growth but facing challenges in net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 8:01 pm

MEDP

Medpace Holdings (NASDAQ:MEDP) has received diverse analyst ratings over the last three months, with a shift towards a more bullish outlook. The average 12-month price target for MEDP has increased by 22.55% to $413.0. Analysts from UBS and Baird have raised their price targets, reflecting positive sentiment towards the company's performance, including a solid revenue growth rate of 26.47% and a high net margin of 15.7%. Medpace, a contract research organization, has shown strong financial management with an ROE of 15.2% and an ROA of 4.98%.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 8:01 pm

FHI

Seven analysts have recently updated their ratings on Federated Hermes (NYSE:FHI), showing a mix of perspectives with an average 12-month price target of $37.14, up from $36.80. The updates include raised price targets and ratings, reflecting a cautiously optimistic outlook on the company's performance. Federated Hermes, with $757.6 billion in managed assets, shows a positive revenue trend and strong financial performance indicators such as ROE and ROA, despite a market capitalization below industry averages and a net margin below benchmarks.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 8:00 pm

IDYA

IDEAYA Biosciences (NASDAQ:IDYA) has received diverse analyst ratings over the past three months, with an upward trend in 12-month price targets, now averaging $52.33. This reflects a 29.53% increase from the previous average of $40.40. Analysts from firms including BTIG, JP Morgan, RBC Capital, and Goldman Sachs have adjusted their ratings and price targets, indicating a positive outlook on the company's performance. Despite facing revenue challenges and a net margin below industry averages, IDEAYA's strategic focus on oncology-focused precision medicine and its financial management are noteworthy.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 8:00 pm